Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Current clinical applications of in vivo gene therapy with AAVs
Hereditary diseases are caused by mutations in genes, and more than 7,000 rare diseases
affect over 30 million Americans. For more than 30 years, hundreds of researchers have …
affect over 30 million Americans. For more than 30 years, hundreds of researchers have …
Advancements in AAV-mediated gene therapy for Pompe disease
Pompe disease (glycogen storage disease type II) is caused by mutations in acid α-
glucosidase (GAA) resulting in lysosomal pathology and impairment of the muscular and …
glucosidase (GAA) resulting in lysosomal pathology and impairment of the muscular and …
Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease
Pompe disease is a lysosomal storage disorder caused by acid-α-glucosidase (GAA)
deficiency, leading to glycogen storage. The disease manifests as a fatal cardiomyopathy in …
deficiency, leading to glycogen storage. The disease manifests as a fatal cardiomyopathy in …
Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease
In Pompe disease, the deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA)
causes skeletal and cardiac muscle weakness, respiratory failure, and premature death …
causes skeletal and cardiac muscle weakness, respiratory failure, and premature death …
Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: preclinical to clinical planning
M Corti, B Cleaver, N Clement, TJ Conlon… - Human Gene …, 2015 - liebertpub.com
A recombinant serotype 9 adeno-associated virus (rAAV9) vector carrying a transgene that
expresses codon-optimized human acid alpha-glucosidase (hGAA, or GAA) driven by a …
expresses codon-optimized human acid alpha-glucosidase (hGAA, or GAA) driven by a …
[HTML][HTML] Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy
Pompe disease is a neuromuscular disease caused by a deficiency of the lysosomal
enzyme acid alpha-glucosidase leading to lysosomal and cytoplasmic glycogen …
enzyme acid alpha-glucosidase leading to lysosomal and cytoplasmic glycogen …
Correcting N euromuscular D eficits W ith G ene T herapy in P ompe D isease
Objective We have recently reported on the pathology of the neuromuscular junction (NMJ)
in Pompe disease, reflecting disruption of neuronal and muscle homeostasis as a result of …
in Pompe disease, reflecting disruption of neuronal and muscle homeostasis as a result of …
Copackaged AAV9 vectors promote simultaneous immune tolerance and phenotypic correction of Pompe disease
Pompe disease is a progressive neuromuscular disorder caused by lysosomal accumulation
of glycogen from a deficiency in acid alpha-glucosidase (GAA). Replacement of the missing …
of glycogen from a deficiency in acid alpha-glucosidase (GAA). Replacement of the missing …
Motor planning perturbation: muscle activation and reaction time
Reaction time (RT) is the time interval between the appearance of a stimulus and initiation of
a motor response. Within RT, two processes occur, selection of motor goals and motor …
a motor response. Within RT, two processes occur, selection of motor goals and motor …
Electrodiagnostic evaluation of individuals implanted with extracellular matrix for the treatment of volumetric muscle injury: case series
N Han, MA Yabroudi, K Stearns-Reider… - Physical …, 2016 - academic.oup.com
Background Electrodiagnosis can reveal the nerve and muscle changes following surgical
placement of an extracellular matrix (ECM) bioscaffold for treatment of volumetric muscle …
placement of an extracellular matrix (ECM) bioscaffold for treatment of volumetric muscle …